Casma Therapeutics Stock

casmatx.comHealthcareFounded: 2017

Casma Therapeutics is a biopharma technology company that focuses on removal of damaged cell components to treat and prevent various diseases. Casma Therapeutics aims to reprogram autophagy methods, also known as the removal of infiltrates of cells that can damage and degrade them. The private company has brought together a team of clinical specialists and scientists all with a mission to treat patients where traditional drugs have failed.

Register for Details

For more details on financing and valuation for Casma Therapeutics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Casma Therapeutics.

Register Today

Casma Therapeutics investors also invested in these private companies


Management Team

Daniel Ory
Chief Medical Officer
Frank Gentile
Chief Operating Officer
Keith Dionne
Chief Executive Officer
Leon Murphy
Chief Scientific Officer

Board Members

Bob Tepper
Third Rock Ventures
Cary Pfeffer
Third Rock Ventures
Finny Kuruvilla
Eventide Funds
Gladys Nunez
Hiromichi Kimura
Independent Director
Millie Ray
The Column Group
Nagesh Mahanthappa
Scholar Rock, Inc.
Tomotaka Okino

Other companies like Casma Therapeutics in the Healthcare sector

Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation


New investors participating in the round include Amgen Ventures, LLC, Astellas Venture Management, Eisai Co., Ltd., Euclidean Capital, Mirae Asset, and Ono Venture Investment.